Celcuity
CELC | NASDAQ
$60.57
-$3.80 (-5.90%)
At close: Nov 16, 2026, 4:00 PM ET
$60.57
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:41 PM ET
Celcuity Company Profile
Company profile explainedCompany Profile
Celcuity, Inc. operates as a cellular analysis company. The company discovers new cancer sub-types and commercializing diagnostic tests designed to improve the clinical outcomes of cancer patients treated with targeted therapies. The firm's proprietary CELx diagnostic platform is the commercially ready technology that uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the targeted therapy that treats it. The company was founded by Brian F. Sullivan and Lance G. Laing in January 2012 and is headquartered in Minneapolis, MN.
Key Executives
| Name | Position |
|---|---|
| Brian F. Sullivan | Co-Founder, Chairman & Chief Executive Officer |
| Vicky Hahne | Chief Financial Officer |
| Brent Eilefson | General Counsel & Chief Compliance Officer |
| Byron Robinson | Chief Strategy Officer |
| Eldon C. Mayer | Chief Commercial Officer |
| Igor Gorbatchevsky | Chief Medical Officer |
| Jodi Sievers | Head of Investor Relations & Corporate Communications |
| Lance G. Laing | Co-Founder, Chief Science Officer, Vice President, Secretary & Director |
| Sheri Smith | Acting Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Oct 09, 2026 | 4 | Filing |
| Oct 05, 2026 | 4 | Filing |
| Oct 05, 2026 | 3 | Filing |
| Oct 02, 2026 | 8-K | Current Report |
| Sep 30, 2026 | 8-K | Current Report |
| Aug 26, 2026 | 8-K | Current Report |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 18, 2026 | 4 | Filing |
| Aug 13, 2026 | 10-Q | Quarterly Report |
Celcuity
| Country | United States |
| IPO Date | Sep 19, 2017 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 155 |
| CEO | Brian F. Sullivan |
Contact Details
2800 Campus Drive Minneapolis,
Minnesota 55441 United States
Stock Details
| Ticker Symbol | CELC |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001603454 |
| CUSIP Number | 15102K100 |
| ISIN Number | US15102K1007 |
| SIC Code | 8071 |
Recent News
- 8 days ago / globenewswire.comCelcuity Announces FDA Acceptance of sNDA for REVTORPYK™ (gedatolisib) for HR+/HER2-, PIK3CA Mutant Locally Advanced or Metastatic Breast Cancer
- 8 days ago / seekingalpha.comCelcuity Inc. (CELC) Q3 2026 Earnings Call Transcript
- 11 days ago / marketbeat.comWhat Celcuity (CELC) Said on Its Q3 Earnings Call
- 14 days ago / globenewswire.comCelcuity To Participate in Upcoming Investor Conferences
- 18 days ago / seekingalpha.comCelcuity: Stronger Clinical Evidence, Much Lower Valuation
- 19 days ago / globenewswire.comCelcuity Schedules Release of Third Quarter 2026 Financial Results and Webcast/Conference Call
- 24 days ago / globenewswire.comCelcuity Presents Updated Results from the PIK3CA MT Cohort of the Phase 3 VIKTORIA-1 Study in Patients with HR+/HER2- Advanced Breast Cancer at the ESMO Congress 2026
- 25 days ago / globenewswire.comCelcuity Presents Updated Data from a Phase 1b/2 Study Evaluating Gedatolisib Plus Darolutamide in Men with Metastatic Castration-Resistant Prostate Cancer at the ESMO Congress 2026
- 1 month ago / globenewswire.comCelcuity Announces Multiple Presentations At The European Society For Medical Oncology (ESMO) Congress 2026
- 2 months ago / globenewswire.comCelcuity Appoints David Gryska To Its Board Of Directors
Add to Watchlist
Select watchlists to add or remove CELC